The FDA’s roadmap to reduce, refine, and replace animal testing signals a transformative shift in drug development. New Approach Methodologies (NAMs) are now central to delivering safe and effective medicines ethically, while improving the predictive value of preclinical testing.

NAMs are no longer a future promise but are the standard the industry is moving toward. Evotec makes NAMs work for you by uniting advanced in vitro models, high-throughput automation and in silico prediction to deliver insights that regulators trust and innovators depend on. With over 30 years of leadership in drug discovery and development services, Evotec leverages Cyprotex and its global network of scientific excellence to help partners reduce animal testing, accelerate development timelines, and bring safer, more effective medicines to patients worldwide.